Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OFEV vs NINTEDANIB
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Nintedanib is a tyrosine kinase inhibitor that blocks the activity of fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), thereby inhibiting fibroblast proliferation, migration, and transformation, and reducing extracellular matrix deposition.
Nintedanib is a small molecule tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). It also inhibits RET, FLT3, and Src family kinases. These receptors are involved in angiogenesis, proliferation, and fibrosis.
Idiopathic pulmonary fibrosis,Systemic sclerosis-associated interstitial lung disease,Chronic fibrosing interstitial lung diseases with a progressive phenotype
Idiopathic pulmonary fibrosis (IPF),Systemic sclerosis-associated interstitial lung disease (SSc-ILD),Chronic fibrosing interstitial lung diseases with a progressive phenotype,Non-small cell lung cancer (NSCLC) with adenocarcinoma histology (in combination with docetaxel, after first-line chemotherapy, approved in some regions)
150 mg orally twice daily, taken with food.
150 mg orally twice daily approximately 12 hours apart, taken with food.
Terminal elimination half-life is approximately 38 hours (range 30–48 hours) at steady state, supporting once-daily dosing.
Terminal half-life: 9.5 hours (range 6-14 hours) in patients with IPF; supports twice-daily dosing.
Primarily metabolized by esterases (hydrolysis) to free acid BIBF 1202; minor CYP3A4-mediated metabolism; biliary-fecal excretion.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not recommended for use in severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
None
FDA Pregnancy Category D. First trimester: Nintedanib is teratogenic in animal studies, causing embryofetal lethality, structural abnormalities, and reduced fetal weight. Avoid use; if exposure occurs, inform patient of risks. Second/third trimesters: Risk of oligohydramnios, fetal renal impairment, and skeletal malformations; use only if benefit outweighs risk.
Nintedanib is contraindicated in pregnancy. In animal studies, it caused embryo-fetal toxicity and teratogenic effects at exposures below human therapeutic levels. In humans, it is expected to cause fetal harm if administered during pregnancy. Pregnancy must be ruled out before initiation and avoided during treatment.
Monitor liver function tests (ALT, AST, bilirubin) monthly for first 3 months, then every 3 months. GI adverse effects (diarrhea, nausea) are common; consider antiemetics and antidiarrheals. Avoid use in severe hepatic impairment (Child-Pugh C). Nintedanib is a tyrosine kinase inhibitor with anticoagulant effects; monitor for bleeding especially in patients on anticoagulants.
Monitor liver function tests (ALT, AST, bilirubin) before and during treatment; dose reduction or interruption required for moderate hepatic impairment. Check blood pressure regularly due to risk of hypertension and arterial thromboembolic events. Use with caution in patients with bleeding risk or on anticoagulation. Before starting, perform a baseline echocardiogram if history of cardiovascular disease.
No interactions on record
"The serum concentration of Nicardipine can be increased when it is combined with Nintedanib."
"The serum concentration of Losartan can be increased when it is combined with Nintedanib."
"The serum concentration of Desipramine can be increased when it is combined with Nintedanib."
OFEV and NINTEDANIB are distinct pharmacological agents. OFEV belongs to the Tyrosine Kinase Inhibitor class and is primarily used for Idiopathic pulmonary fibrosisSystemic sclerosis-associated interstitial lung diseaseChronic fibrosing interstitial lung diseases with a progressive phenotype. NINTEDANIB belongs to the Tyrosine Kinase Inhibitor class and is primarily used for Idiopathic pulmonary fibrosis (IPF)Systemic sclerosis-associated interstitial lung disease (SSc-ILD)Chronic fibrosing interstitial lung diseases with a progressive phenotypeNon-small cell lung cancer (NSCLC) with adenocarcinoma histology (in combination with docetaxel, after first-line chemotherapy, approved in some regions). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. OFEV carries a safety status of Category C, whereas NINTEDANIB safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Nintedanib is metabolized primarily by esterases (hydrolysis) and to a lesser extent via CYP3A4. The major metabolites are BIBF 1202 (free acid) and its glucuronide conjugate.
Primarily biliary/fecal (~93.4% of total radioactivity recovered in feces), renal excretion is minor (~0.6% unchanged in urine).
Primarily fecal (85%) as unchanged drug; renal excretion accounts for <1%.
Bound primarily to albumin and alpha-1-acid glycoprotein (AAG); total protein binding is approximately 99.8%.
97.8% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
Volume of distribution is approximately 1.8 L/kg (range 1.0–2.5 L/kg) after oral administration, indicating extensive tissue distribution.
Vd: 0.6 L/kg (range 0.4-1.0 L/kg), indicating extensive tissue distribution.
Absolute bioavailability is ~30% (range 23–40%) after oral administration under fed conditions; food increases exposure by approximately 40%.
Oral: 18-34% (mean 24%); food increases systemic exposure by 20% and reduces variability.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild hepatic impairment (Child-Pugh class A), reduce dose to 100 mg twice daily. For moderate hepatic impairment (Child-Pugh class B), not recommended.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 100 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Safety and efficacy not established in pediatric patients; no recommended dosing available.
Safety and efficacy not established in pediatric patients; no recommended dose.
No specific dose adjustment required based on age alone; monitor for adverse effects due to potential decreased renal function.
No specific dose adjustment required based on age alone; monitor tolerability closely due to potential increased risk of gastrointestinal and hepatic adverse effects.
Nintedanib has a boxed warning for hepatotoxicity, including fatal cases. Liver function tests must be monitored before and during treatment. Dose reduction or interruption may be required.
Avoid grapefruit and grapefruit juice as they may increase nintedanib exposure. Take with a meal to improve tolerability and reduce GI side effects.
Take with food to reduce gastrointestinal side effects. Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase nintedanib exposure. Avoid St. John's wort as it may reduce efficacy. No other dietary restrictions.
No human data on excretion in breast milk. M/P ratio not available. Nintedanib is excreted in rat milk. Due to potential for adverse effects (e.g., diarrhea, vomiting, hepatotoxicity) in nursing infants, advise against breastfeeding during treatment and for at least 3 weeks after last dose.
It is unknown whether nintedanib is excreted in human breast milk. Due to potential adverse effects in the nursing infant, breastfeeding is not recommended during treatment and for at least 3 months after the last dose. M/P ratio is not established.
No specific dose adjustment studies in pregnancy. Use lowest effective dose if unavoidable. Increased hepatic clearance in pregnancy may reduce exposure; however, given teratogenicity, avoid use. If used, monitor drug levels (not standard) and adjust based on tolerability (e.g., diarrhea, hepatotoxicity). Pharmacokinetic changes: Increased Vd and clearance theoretically possible, but no data.
Nintedanib should not be used in pregnancy. No dosage adjustments are established as the drug is contraindicated. If inadvertently exposed, immediate discontinuation is recommended. Pharmacokinetic changes in pregnancy are unknown due to lack of data.
Take with food to reduce nausea and diarrhea.,Do not break, crush, or chew capsules; swallow whole.,Report any signs of bleeding (unusual bruising, black/tarry stools, blood in urine) promptly.,Avoid grapefruit juice during treatment.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not take St. John's wort with OFEV.
Take nintedanib exactly as prescribed, usually twice a day with food. Swallow capsules whole with water; do not crush or chew.,Do not take a missed dose if within 6 hours of the next scheduled dose. Do not double the dose.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or severe fatigue.,Monitor for diarrhea and manage with hydration and antidiarrheals; contact your doctor if severe or persistent.,Avoid grapefruit and grapefruit juice during treatment as they may increase nintedanib levels.,Use effective contraception during treatment and for at least 3 months after the last dose; tell your doctor if you become pregnant.,Report any unusual bleeding or bruising, or symptoms of blood clots like sudden chest pain or leg swelling.